- Home
- DVS vs MRVI Comparison
DVS vs MRVI Comparison
Compare DVS & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- MRVI
- Stock Information
- Founded
- DVS 2011
- MRVI 2014
- Country
- DVS Canada
- MRVI United States
- Employees
- DVS N/A
- MRVI N/A
- Industry
- DVS
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- MRVI Health Care
- Exchange
- DVS Nasdaq
- MRVI Nasdaq
- Market Cap
- DVS 401.8M
- MRVI 449.6M
- IPO Year
- DVS N/A
- MRVI 2020
- Fundamental
- Price
- DVS $4.13
- MRVI $3.64
- Analyst Decision
- DVS
- MRVI Hold
- Analyst Count
- DVS 0
- MRVI 9
- Target Price
- DVS N/A
- MRVI $4.54
- AVG Volume (30 Days)
- DVS 775.6K
- MRVI 1.5M
- Earning Date
- DVS 11-21-2025
- MRVI 11-06-2025
- Dividend Yield
- DVS N/A
- MRVI N/A
- EPS Growth
- DVS N/A
- MRVI N/A
- EPS
- DVS N/A
- MRVI N/A
- Revenue
- DVS N/A
- MRVI $192,435,000.00
- Revenue This Year
- DVS N/A
- MRVI N/A
- Revenue Next Year
- DVS N/A
- MRVI $7.27
- P/E Ratio
- DVS N/A
- MRVI N/A
- Revenue Growth
- DVS N/A
- MRVI N/A
- 52 Week Low
- DVS $2.48
- MRVI $1.67
- 52 Week High
- DVS $5.38
- MRVI $6.21
- Technical
- Relative Strength Index (RSI)
- DVS 46.54
- MRVI 67.10
- Support Level
- DVS $4.00
- MRVI $2.55
- Resistance Level
- DVS $4.49
- MRVI $3.33
- Average True Range (ATR)
- DVS 0.22
- MRVI 0.21
- MACD
- DVS 0.03
- MRVI 0.03
- Stochastic Oscillator
- DVS 45.98
- MRVI 97.75
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.